DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MOEXIPRIL HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Moexipril Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00588302	Moexipril for Primary Biliary Cirrhosis	Completed	UCB Pharma	Phase 2	The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA).
NCT00588302	Moexipril for Primary Biliary Cirrhosis	Completed	Mayo Clinic	Phase 2	The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA).
NCT00834067	Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting conditions.
NCT00835042	Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	The objective of this study is to compare the relative bioavailability of Moexipril HCl/hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult non-smoking subjects under fasting conditions.

Clinical Trial Conditions for Moexipril Hydrochloride

Condition Name

Condition Name for Moexipril Hydrochloride
Intervention	Trials
Healthy	4
Primary Biliary Cirrhosis	1
Hypertension	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Moexipril Hydrochloride
Intervention	Trials
Liver Cirrhosis, Biliary	1
Liver Cirrhosis	1
Fibrosis	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Moexipril Hydrochloride

Trials by Country

Trials by Country for Moexipril Hydrochloride
Location	Trials
United States	8

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Moexipril Hydrochloride
Location	Trials
Pennsylvania	2
Texas	2
Missouri	2
Nebraska	1
Minnesota	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Moexipril Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Moexipril Hydrochloride
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1
Phase 1	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Moexipril Hydrochloride
Clinical Trial Phase	Trials
Completed	5
Enrolling by invitation	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Moexipril Hydrochloride

Sponsor Name

Sponsor Name for Moexipril Hydrochloride
Sponsor	Trials
Paddock Laboratories, Inc.	2
Teva Pharmaceuticals USA	2
University of Nebraska	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Moexipril Hydrochloride
Sponsor	Trials
Industry	5
Other	2

Export unavailable in trial.
Subscribe for complete access.